ISSN 1662-4009 (online)

ey0016.10-2 | (1) | ESPEYB16

10.2. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial

Tauschmann Martin , Bally Hood Thabit Lia , Allen Janet M , Hartnell Sara , Wilinska Malgorzata E , Ruan Yue , Sibayan Judy , Kollman Craig , Cheng Peiyao , Beck Roy W , Acerini Carlo L , Evans Mark L , Dunger David B , Elleri Daniela , Campbell Fiona , Bergenstal Richard M , Criego Amy , Shah Viral N , Leelarathna Lalantha , Hovork Roman , APCam Consortium Roman

To read the full abstract: Lancet. 2018 Oct 13; 392(10155): 1321–1329The appearance of new technologies and treatment modalities are changing the fate of patients with diabetes. While until recently the global epidemic of type 1 diabetes (T1D) has been largely neglected (1), much data are being published on the impact of new technologies on metabolic control, quality of life and mic...